Global Human Growth Hormone Market Report ----------------------------------------- 215
Executive Summary Pituitary - the master gland of human body is responsible for controlling crucial hormonal secretion, which, in turn, regulates other key aspects of the body such as temperature, growth, thyroid functioning, urination, and production of other hormones. It is a pea sized gland situated at the base of brain and is a major component of human body as it expedites the response towards the surrounding environment and settings. Any deformity or damage to the pituitary gland can adversely impact the production and activity level of the above mentioned hormones, thereby affecting the body work process and stunting the outcomes especially in the case of growth hormone. Marred pituitary function leads to either over or under secretion of the somatropin that is the growth hormone. Its over secretion causes disfiguration in the body parts like hands, face, feet, etc. whereas, its deficiency impedes the growth of body parts/whole body, thus leading to disease states like dwarfism or gigantism. It is observed that the growth hormone related problems usually affect children and teenagers, but it is seen to grip adults as well though to a lesser extent. The major factors which vitiate the pituitary operations thus impairing the GH role include kidney malfunction, tumors/cancer especially associated with brain. There are some other unknown causes as well which are termed as idiopathic. Earlier, to deal with these predicaments, growth hormone used to be extracted from the human cadavers but, as time passed and evolution of technology/tools/techniques/r&d took place, the extraction of GH also got altered and many novel innovations and discoveries were made in the respective field. Nowadays, many leading companies are heavily involved in the R&D process for devising longer acting and sustained release versions of the somatropin which are produced using the recombinant technology. The competition prevalent in the respective industry is heating up day by day. The human growth hormone market is monopolized by a few players viz. Pfizer, NovoNordisk, Eli Lilly, Sandoz and Roche. The global HGH report discusses the key ongoing trends like global agreement for Long-Acting Human Growth Hormone (HGH-CTP), increasing use of biosimilar version of drugs and continuous growth of recombinant growth hormones market. On the industry development front, the current inclination is towards developing better treatments for Alzheimer s disease and advancements in needle free injections technology. Furthermore, the major factors driving the HGH market include rising cancer and CKD/ESRD cases and increasing healthcare expenditure on worldwide basis. In addition, a few factors posing challenges in front of the HGH industry are the problems in diagnosis of growth hormone deficiency, risks associated with use of recombinant growth hormone therapies and off-label HGH use which, to an extent, are hindering the growth and development of the same. By combining SPSS Inc. s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.
Kilograms (Kg) US$ Billion The Growth Hormone market is expected to grow on account of long acting therapies and the growth is also coming from approval of new agents Global Human Growth Hormones Market by Value (21-215*) 3.5 2 3 1 2.5 1% 2 1.5 % 1 -.5-1% -1 Value Global Human Growth Hormones Market by Volume (21-215*) In 214, the global market for human growth hormone reached US$... billion based on key drug sales, a decline of % compared to US$... billion in 213 registering a CAGR of % from 21-214. The HGH market reached Kg in terms of volume from Kg in the previous fiscal registering an annual growth rate of %. During 21-214, the market registered a CAGR of %. The key products representing global HGH market included NovoNordisk s Norditropin, which constituted around..% of the global market share, Pfizer s Genotropin with..%, followed by Eli Lilly s Humatrope with..% and Sandoz s Omnitrope with..% share in 214. The human growth hormone market grew rigorously in the developed geographies like the US, Canada, Europe, and Japan. Global HGH Market Share (214) 8 7 6 5 4 3 2 1 a Volume 1 1 1 1% % - Novo Nordisk Pfizer Lilly Sandoz Merck Kgaa Roche Others
US$ Million US$ Million In 214, the global market for human growth hormone reached US$... billion based on key drug sales. Global HGH by Growth Disorder Indication ( 215E) Pediatric GHD Idiopathic Short Stature Turner Syndrome Adult GHD Prader-Willi Short for Gestational Age Others Worldwide Pediatric GHD Market Opportunity (214-212E) The primary indications in children are pediatric GHD which is estimated to have a maximum contribution of % followed by idiopathic short stature (ISS) with a contribution of % of the total revenue. The third highest contributor is Turner syndrome with % share. The global market is estimated to be split roughly by..-..% use in pediatrics and..-..% use in adults. The worldwide pediatric growth hormone deficiency market is estimated to grow to US$... million by 22 from US$... million in 214. The estimated annual growth rate was..% for 214. The US pediatric GHD market is estimated to reach US$... million in 22 from US$... million in 214. The annual growth rate for 214 stood at % and is estimated to reach % by 22. The U.S. Pediatric GHD Market (214-22E) 25 2 15 1 5 Value 7% 3% 1% % 8 7 6 5 4 3 2 1 1 1 1% %
US$ Million US$ Billion US$ Million Given the multiple diseases that can be treated with rgh and concordant increasing use of treatment, the market has been growing continuously 9 8 7 6 5 4 3 2 1 European Pediatric GHD Market (214-22E) 3% 1% % The European pediatric GHD market is estimated to reach US$... million by 22 from US$... million in 214. The market is estimated to experience modest growth along with estimated penetration of..% within 7 years from 214. Japan s market for GHD is estimated to reach US$... million by 22 from US$... million in 214. The annual growth rate for 214 stood at %. After the anticipated launch, the global opportunity for VRS-317 is estimated to be US$... million for the year 218, and is further expected to be worth US$... million by 224, at a CAGR of %. The global HGH market is forecasted to reach US$... billion in 218 as compared to US$... billion in 215.The same is expected to record a CAGR of about % for the period spanning 212 to 218. Japan s Pediatric GHD Market (214-22E) Global Human Growth Hormones Market Forecast (212-218E) 4 8 3.5 6 3 4 2.5 2 2 1.5 % 1.5